Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Rating of “Buy” by Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $86.80.

Several research firms recently issued reports on GPCR. Morgan Stanley began coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. JMP Securities dropped their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd.

Institutional Trading of Structure Therapeutics

A number of large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its stake in Structure Therapeutics by 99.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,460 shares of the company’s stock valued at $503,000 after purchasing an additional 5,707 shares during the period. abrdn plc raised its holdings in shares of Structure Therapeutics by 132.7% during the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the period. Bank Pictet & Cie Europe AG bought a new position in Structure Therapeutics in the 3rd quarter worth approximately $206,000. Finally, Griffin Asset Management Inc. bought a new position in Structure Therapeutics in the 3rd quarter worth approximately $634,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $37.59 on Friday. Structure Therapeutics has a 1 year low of $26.61 and a 1 year high of $75.02. The firm’s 50-day simple moving average is $39.62 and its 200-day simple moving average is $39.78. The firm has a market cap of $1.75 billion, a PE ratio of -48.82 and a beta of -3.53.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, equities analysts predict that Structure Therapeutics will post -0.79 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.